Reference(s)
Click here to return to the Reference Table

Cancer type: Melanoma


HGF/SF expression

Reference Number: 202
Hendrix, M. J. et al. Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/scatter factor (HGF/SF). Am J Pathol 152, 855-63. (1998).
PubMed link      E-mail link

Reference Number: 338
Nambiar S, Mirmohammadsadegh A, Doroudi R, Gustrau A, Marini A, Roeder G, Ruzicka T, Hengge UR.Signaling networks in cutaneous melanoma metastasis identified by complementary DNA microarrays. Arch Dermatol. 141, 165-73 (2005)
PubMed link      E-mail link

Reference Number: 412
Wolnicka-Glubisz A, Noonan FP. Neonatal susceptibility to UV induced cutaneous malignant melanoma in a mouse model. Photochem Photobiol Sci. 5 254-60 (2006)
PubMed link      E-mail link

Reference Number: 419
Poon VK, Huang L, Burd A. Biostimulation of dermal fibroblast by sublethal Q-switched Nd:YAG 532 nm laser: collagen remodeling and pigmentation. J Photochem Photobiol B. 81, 1-8 (2005)
PubMed link      E-mail link

Reference Number: 420
Cools-Lartigue J, Marshall JC, Caissie AL, Saraiva VS, Burnier MN Jr. Secretion of hepatocyte growth factor and vascular endothelial growth factor during uveal melanoma-monocyte in vitro interactions. Melanoma Res.15, 141-5 (2005)
PubMed link      E-mail link

Reference Number: 523
Gao L, Feng Y, Bowers R, Becker-Hapak M, Gardner J, Council L, Linette G, Zhao H, Cornelius LA. Ras-associated protein-1 regulates extracellular signal-regulated kinase activation and migration in melanoma cells: two processes important to melanoma tumorigenesis and metastasis. Cancer Res. 66, 7880-8 (2006)
PubMed link      E-mail link

Reference Number: 524
Tormo D, Ferrer A, Gaffal E, Wenzel J, Basner-Tschakarjan E, Steitz J, Heukamp LC, Gütgemann I, Buettner R, Malumbres M, Barbacid M, Merlino G, Tüting T. Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation. Am J Pathol. 169, 665-72 (2006)
PubMed link      E-mail link

Reference Number: 525
Tormo D, Ferrer A, Bosch P, Gaffal E, Basner-Tschakarjan E, Wenzel J, Tüting T. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. Cancer Res. 66, 5427-35 (2006)
PubMed link      E-mail link

Reference Number: 543
Gaggioli C, Deckert M, Robert G, Abbe P, Batoz M, Ehrengruber MU, Ortonne JP, Ballotti R, Tartare-Deckert S. HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1. Oncogene. 24, 1423-33 (2005)
PubMed link      E-mail link

Reference Number: 869
Damm S, Koefinger P, Stefan M, Wels C, Mehes G, Richtig E, Kerl H, Otte M, Schaider H. HGF-promoted motility in primary human melanocytes depends on CD44v6 regulated via NF-kappa B, Egr-1, and C/EBP-beta. J Invest Dermatol. 130, 1893-903 (2010)
PubMed link      E-mail link

Reference Number: 871
Topcu-Yilmaz P, Kiratli H, Saglam A, Söylemezoglu F, Hascelik G. Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma. Melanoma Res. 20, 126-32 (2010)
PubMed link      E-mail link

Reference Number: 883
Oka M, Kikkawa U, Nishigori C. Protein kinase C-betaII represses hepatocyte growth factor-induced invasion by preventing the association of adapter protein Gab1 and phosphatidylinositol 3-kinase in melanoma cells. J Invest Dermatol. 128, 188-95 (2008)
PubMed link      E-mail link

Reference Number: 1206
Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 487, 500-4 (2012)
PubMed link      E-mail link

Reference Number: 1207
Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 487, 505-9 (2012)
PubMed link      E-mail link

Reference Number: 1535
Kwon MJ, Kim DH, Park HR, Shin HS, Kwon JH, Lee DJ, Kim JH, Cho SJ, Nam ES. Frequent hepatocyte growth factor overexpression and low frequency of c-Met gene amplification in human papillomavirus-negative tonsillar squamous cell carcinoma and their prognostic significances. Hum Pathol. 45, 1327-38 (2014)
PubMed link      E-mail link

Reference Number: 1607
Lezcano C, Lee CW, Larson AR, Menzies AM, Kefford RF, Thompson JF, Mihm MC Jr, Ogino S, Long GV, Scolyer RA, Murphy GF. Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. Mod Pathol. 27, 1193-202 (2014)
PubMed link      E-mail link

Reference Number: 1731
Cheng H, Terai M, Kageyama K, Ozaki S, McCue PA, Sato T, Aplin AE Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma. Cancer Res. 75, 2737-48 (2015)
PubMed link      E-mail link

Reference Number: 1776
Hwang S, Kim HE, Min M, Raghunathan R, Panova IP, Munshi R, Ryu B. Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma. J Invest Dermatol. 135, 2283-91 (2015)
PubMed link      E-mail link

Reference Number: 1891
Fedorenko IV, Wargo JA, Flaherty KT, Messina JL, Smalley KS. BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape. J Invest Dermatol. 135, 3115-24 (2015)
PubMed link      E-mail link

Met expression

Reference Number: 203
Natali, P. G. et al. Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. Br J Cancer 68, 746-50. (1993).
PubMed link      E-mail link

Reference Number: 338
Nambiar S, Mirmohammadsadegh A, Doroudi R, Gustrau A, Marini A, Roeder G, Ruzicka T, Hengge UR.Signaling networks in cutaneous melanoma metastasis identified by complementary DNA microarrays. Arch Dermatol. 141, 165-73 (2005)
PubMed link      E-mail link

Reference Number: 414
McGill GG, Haq R, Nishimura EK, Fisher DE. c-Met expression is regulated by Mitf in the melanocyte lineage. J Biol Chem. 281, 10365-73 (2006)
PubMed link      E-mail link

Reference Number: 836
Abdel-Rahman MH, Boru G, Massengill J, Salem MM, Davidorf FH. MET oncogene inhibition as a potential target of therapy for uveal melanomas. Invest Ophthalmol Vis Sci. 51, 3333-9 (2010)
PubMed link      E-mail link

Reference Number: 870
Mascarenhas JB, Littlejohn EL, Wolsky RJ, Young KP, Nelson M, Salgia R, Lang D. PAX3 and SOX10 activate MET receptor expression in melanoma. Pigment Cell Melanoma Res. 23, 225-37 (2010)
PubMed link      E-mail link

Reference Number: 871
Topcu-Yilmaz P, Kiratli H, Saglam A, Söylemezoglu F, Hascelik G. Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma. Melanoma Res. 20, 126-32 (2010)
PubMed link      E-mail link

Reference Number: 872
Stevens L, McClelland L, Fricke A, Williamson M, Kuo I, Scott G. Plexin B1 suppresses c-Met in melanoma: a role for plexin B1 as a tumor-suppressor protein through regulation of c-Met. J Invest Dermatol. 130, 1636-45 (2010)
PubMed link      E-mail link

Reference Number: 881
Beuret L, Flori E, Denoyelle C, Bille K, Busca R, Picardo M, Bertolotto C, Ballotti R. Up-regulation of MET expression by alpha-melanocyte-stimulating hormone and MITF allows hepatocyte growth factor to protect melanocytes and melanoma cells from apoptosis. J Biol Chem. 282, 14140-7 (2007)
PubMed link      E-mail link

Reference Number: 882
Mallikarjuna K, Pushparaj V, Biswas J, Krishnakumar S. Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: an immunohistochemical study. Curr Eye Res. 32, 281-90 (2007)
PubMed link      E-mail link

Reference Number: 966
Vanbrocklin MW, Robinson JP, Whitwam T, Guilbeault AR, Koeman J, Swiatek PJ, Vande Woude GF, Khoury JD, Holmen SL. Met amplification and tumor progression in Cdkn2a-deficient melanocytes. Pigment Cell Melanoma Res. 22, 454-60 (2009)
PubMed link      E-mail link

Reference Number: 1105
Comito G, Calvani M, Giannoni E, Bianchini F, Calorini L, Torre E, Migliore C, Giordano S, Chiarugi P. HIF-1a stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells. Free Radic Biol Med. 51, 893-904 (2011)
PubMed link      E-mail link

Reference Number: 1142
Syed ZA, Yin W, Hughes K, Gill JN, Shi R, Clifford JL. HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop. BMC Cancer. 11, 180 (2011)
PubMed link      E-mail link

Reference Number: 1164
Dong F, Lou D. MicroRNA-34b/c suppresses uveal melanoma cell proliferation and migration through multiple targets. Mol Vis. 18, 537-46 (2012)
PubMed link      E-mail link

Reference Number: 1165
Chattopadhyay C, Ellerhorst JA, Ekmekcioglu S, Greene VR, Davies MA, Grimm EA. Association of activated c-Met with NRAS-mutated human melanomas. Int J Cancer. 131, E56-65 (2012)
PubMed link      E-mail link

Reference Number: 1166
Wu X, Zhou J, Rogers AM, Jänne PA, Benedettini E, Loda M, Hodi FS. c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential. Melanoma Res. 22, 123-32 (2012)
PubMed link      E-mail link

Reference Number: 1188
Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G, Ghajar C, Nitadori-Hoshino A, Hoffman C, Badal K, Garcia BA, Callahan MK, Yuan J, Martins VR, Skog J, Kaplan RN, Brady MS, Wolchok JD, Chapman PB, Kang Y, Bromberg J, Lyden D. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 18, 883-91 (2012)
PubMed link      E-mail link

Reference Number: 1189
Thu YM, Su Y, Yang J, Splittgerber R, Na S, Boyd A, Mosse C, Simons C, Richmond A. NF-?B inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the ß-catenin pathway. Oncogene. 31, 2580-92 (2012)
PubMed link      E-mail link

Reference Number: 1322
Luo C, Tetteh PW, Merz PR, Dickes E, Abukiwan A, Hotz-Wagenblatt A, Holland-Cunz S, Sinnberg T, Schittek B, Schadendorf D, Diederichs S, Eichmüller SB. miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes. J Invest Dermatol. 133, 768-75 (2013)
PubMed link      E-mail link

Reference Number: 1323
Swoboda A, Schanab O, Tauber S, Bilban M, Berger W, Petzelbauer P, Mikula M. MET expression in melanoma correlates with a lymphangiogenic phenotype. Hum Mol Genet. 21, 3387-96 (2012)
PubMed link      E-mail link

Reference Number: 1535
Kwon MJ, Kim DH, Park HR, Shin HS, Kwon JH, Lee DJ, Kim JH, Cho SJ, Nam ES. Frequent hepatocyte growth factor overexpression and low frequency of c-Met gene amplification in human papillomavirus-negative tonsillar squamous cell carcinoma and their prognostic significances. Hum Pathol. 45, 1327-38 (2014)
PubMed link      E-mail link

Reference Number: 1546
Surriga O, Rajasekhar VK, Ambrosini G, Dogan Y, Huang R, Schwartz GK. Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model. Mol Cancer Ther. 12, 2817-26 (2014)
PubMed link      E-mail link

Reference Number: 1665
Gangemi R, Amaro A, Gino A, Barisione G, Fabbi M, Pfeffer U, Brizzolara A, Queirolo P, Salvi S, Boccardo S, Gualco M, Spagnolo F, Jager MJ, Mosci C, Rossello A, Ferrini S. ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion. Pigment Cell Melanoma Res. 27, 1138-48 (2014)
PubMed link      E-mail link

Reference Number: 1731
Cheng H, Terai M, Kageyama K, Ozaki S, McCue PA, Sato T, Aplin AE Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma. Cancer Res. 75, 2737-48 (2015)
PubMed link      E-mail link

Reference Number: 1764
Gardner FP, Serie DJ, Salomao DR, Wu KJ, Markovic SN, Pulido JS, Joseph RW. c-MET expression in primary and liver metastases in uveal melanoma. Melanoma Res. 24, 617-20 (2015)
PubMed link      E-mail link

Reference Number: 1851
Kubic JD, Little EC, Lui JW, Iizuka T, Lang D. PAX3 and ETS1 synergistically activate MET expression in melanoma cells. Oncogene. 34, 4964-74 (2015)
PubMed link      E-mail link

Reference Number: 1852
Barisione G, Fabbi M, Gino A, Queirolo P, Orgiano L, Spano L, Picasso V, Pfeffer U, Mosci C, Jager MJ, Ferrini S, Gangemi R. Potential Role of Soluble c-Met as a New Candidate Biomarker of Metastatic Uveal Melanoma. JAMA Ophthalmol. 133, 1013-21 (2015)
PubMed link      E-mail link

Poor Prognosis

Mutation of Met

In vitro studies

Reference Number: 204
Halaban, R. et al. Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells. Oncogene 7, 2195-206. (1992).
PubMed link      E-mail link

Reference Number: 205
Halaban, R., Rubin, J. S. & White, W. met and HGF-SF in normal melanocytes and melanoma cells. Exs 65, 329-39 (1993).
PubMed link      E-mail link

Reference Number: 271
Recio JA, Merlino G. Hepatocyte growth factor/scatter factor induces feedback up-regulation of CD44v6 in melanoma cells through Egr-1. Cancer Res 63:1576-82 (2003).
PubMed link      E-mail link

Reference Number: 413
Ferraro D, Corso S, Fasano E, Panieri E, Santangelo R, Borrello S, Giordano S, Pani G, Galeotti T. Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS). Oncogene. 25, 3689-98 (2006)
PubMed link      E-mail link

Reference Number: 419
Poon VK, Huang L, Burd A. Biostimulation of dermal fibroblast by sublethal Q-switched Nd:YAG 532 nm laser: collagen remodeling and pigmentation. J Photochem Photobiol B. 81, 1-8 (2005)
PubMed link      E-mail link

Reference Number: 420
Cools-Lartigue J, Marshall JC, Caissie AL, Saraiva VS, Burnier MN Jr. Secretion of hepatocyte growth factor and vascular endothelial growth factor during uveal melanoma-monocyte in vitro interactions. Melanoma Res.15, 141-5 (2005)
PubMed link      E-mail link

Reference Number: 1041
Yang D, Tao J, Li L, Kedei N, Tóth ZE, Czap A, Velasquez JF, Mihova D, Michalowski AM, Yuspa SH, Blumberg PM. RasGRP3, a Ras activator, contributes to signaling and the tumorigenic phenotype in human melanoma. Oncogene. 30, 4590-600 (2011)
PubMed link      E-mail link

Reference Number: 1142
Syed ZA, Yin W, Hughes K, Gill JN, Shi R, Clifford JL. HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop. BMC Cancer. 11, 180 (2011)
PubMed link      E-mail link

Reference Number: 1452
Furukawa K1, Kambe M, Miyata M, Ohkawa Y, Tajima O, Furukawa K. Ganglioside GD3 induces convergence and synergism of adhesion and hepatocyte growth factor/Met signals in melanomas. Cancer Sci. 105, 52-63 (2014)
PubMed link      E-mail link

Animal models

Reference Number: 28
Takayama, H. et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A 94, 701-6 (1997).
PubMed link      E-mail link

Reference Number: 206
Noonan, F. P., Otsuka, T., Bang, S., Anver, M. R. & Merlino, G. Accelerated ultraviolet radiation-induced carcinogenesis in hepatocyte growth factor/scatter factor transgenic mice. Cancer Res 60, 3738-43 (2000).
PubMed link      E-mail link

Reference Number: 207
Noonan, F. P., Dudek, J., Merlino, G. & De Fabo, E. C. Animal models of melanoma: an HGF/SF transgenic mouse model may facilitate experimental access to UV initiating events. Pigment Cell Res 16, 16-25. (2003).
PubMed link      E-mail link

Reference Number: 208
Otsuka, T. et al. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res 58, 5157-67 (1998).
PubMed link      E-mail link

Reference Number: 209
Recio, J. A. & Merlino, G. Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene 21, 1000-8. (2002).
PubMed link      E-mail link

Reference Number: 210
Yu, Y. & Merlino, G. Constitutive c-Met signaling through a nonautocrine mechanism promotes metastasis in a transgenic transplantation model. Cancer Res 62, 2951-6. (2002).
PubMed link      E-mail link

Reference Number: 412
Wolnicka-Glubisz A, Noonan FP. Neonatal susceptibility to UV induced cutaneous malignant melanoma in a mouse model. Photochem Photobiol Sci. 5 254-60 (2006)
PubMed link      E-mail link

Reference Number: 524
Tormo D, Ferrer A, Gaffal E, Wenzel J, Basner-Tschakarjan E, Steitz J, Heukamp LC, Gütgemann I, Buettner R, Malumbres M, Barbacid M, Merlino G, Tüting T. Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation. Am J Pathol. 169, 665-72 (2006)
PubMed link      E-mail link

Reference Number: 525
Tormo D, Ferrer A, Bosch P, Gaffal E, Basner-Tschakarjan E, Wenzel J, Tüting T. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. Cancer Res. 66, 5427-35 (2006)
PubMed link      E-mail link

Reference Number: 605
Florell SR, Thomas J, Grossman D. Predominant formation of heavily pigmented dermal melanocytomas resembling 'animal-type' melanomas in hepatocyte growth factor (C57BL/6 x C3H)F1 mice following neonatal UV irradiation. J Cutan Pathol. 34, 667-74 (2007)
PubMed link      E-mail link

Reference Number: 868
Kenessey I, Keszthelyi M, Krámer Z, Berta J, Adám A, Dobos J, Mildner M, Flachner B, Cseh S, Barna G, Szokol B, Orfi L, Kéri G, Döme B, Klepetko W, Tímár J, Tóvári J. Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma. Curr Cancer Drug Targets. 10, 332-42 (2010)
PubMed link      E-mail link

Reference Number: 1277
Jarrett SG, Novak M, Harris N, Merlino G, Slominski A, Kaetzel DM. NM23 deficiency promotes metastasis in a UV radiation-induced mouse model of human melanoma. Clin Exp Metastasis. 30, 25-36 (2013)
PubMed link      E-mail link

Reference Number: 1606
Wolnicka-Glubisz A, Strickland FM, Wielgus A, Anver M, Merlino G, De Fabo EC, Noonan FP. A melanin-independent interaction between Mc1r and Met signaling pathways is required for HGF-dependent melanoma. Int J Cancer. 136, 752-60 (2015)
PubMed link      E-mail link

Therapeutic Development

Reference Number: 22
Jakubczak, J. L., LaRochelle, W. J. & Merlino, G. NK1, a natural splice variant of hepatocyte growth factor/scatter factor, is a partial agonist in vivo. Mol Cell Biol 18, 1275-83. (1998).
PubMed link      E-mail link

Reference Number: 38
Fazekas, K., Raso, E., Zarandi, M., Dudas, J. & Timar, J. Basic HGF-like peptides inhibit generation of liver metastases in murine and human tumor models. Anticancer Res 22, 2575-9 (2002).
PubMed link      E-mail link

Reference Number: 868
Kenessey I, Keszthelyi M, Krámer Z, Berta J, Adám A, Dobos J, Mildner M, Flachner B, Cseh S, Barna G, Szokol B, Orfi L, Kéri G, Döme B, Klepetko W, Tímár J, Tóvári J. Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma. Curr Cancer Drug Targets. 10, 332-42 (2010)
PubMed link      E-mail link

Reference Number: 873
Yamamoto BJ, Elias PD, Masino JA, Hudson BD, McCoy AT, Anderson ZJ, Varnum MD, Sardinia MF, Wright JW, Harding JW. The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor. J Pharmacol Exp Ther. 333, 161-73 (2010)
PubMed link      E-mail link

Reference Number: 880
Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, Krausz T, Jagadeeswaran R, Salgia R. c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res. 13, 2246-53 (2007)
PubMed link      E-mail link

Reference Number: 1139
Vergani E, Vallacchi V, Frigerio S, Deho P, Mondellini P, Perego P, Cassinelli G, Lanzi C, Testi MA, Rivoltini L, Bongarzone I, Rodolfo M. Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia. 13, 1132-42 (2011)
PubMed link      E-mail link

Reference Number: 1182
Kawas LH, McCoy AT, Yamamoto BJ, Wright JW, Harding JW. Development of angiotensin IV analogs as hepatocyte growth factor/Met modifiers. J Pharmacol Exp Ther. 340, 539-48 (2012)
PubMed link      E-mail link

Reference Number: 1206
Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 487, 500-4 (2012)
PubMed link      E-mail link

Reference Number: 1207
Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 487, 505-9 (2012)
PubMed link      E-mail link

Reference Number: 1233
Samadi AK, Cohen SM, Mukerji R, Chaguturu V, Zhang X, Timmermann BN, Cohen MS, Person EA. Natural withanolide withaferin A induces apoptosis in uveal melanoma cells by suppression of Akt and c-MET activation. Tumour Biol. 33, 1179-89 (2012)
PubMed link      E-mail link

Reference Number: 1478
Jubb AM, Ribas A, Sosman JA, McArthur GA, Yan Y, Rost S, Zhao S, Koeppen H. Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma. Histopathology. 63, 351-61 (2013)
PubMed link      E-mail link

Reference Number: 1546
Surriga O, Rajasekhar VK, Ambrosini G, Dogan Y, Huang R, Schwartz GK. Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model. Mol Cancer Ther. 12, 2817-26 (2014)
PubMed link      E-mail link

Reference Number: 1664
Etnyre D, Stone AL, Fong JT, Jacobs RJ, Uppada SB, Botting GM, Rajanna S, Moravec DN, Shambannagari MR, Crees Z, Girard J, Bertram C, Puri N. Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy. Cancer Biol Ther. 15, 1129-41 (2015)
PubMed link      E-mail link

Reference Number: 1796
Yeh I, Botton T, Talevich E, Shain AH, Sparatta AJ, de la Fouchardiere A, Mully TW, North JP, Garrido MC, Gagnon A, Vemula SS, McCalmont TH, LeBoit PE, Bastian BC. Activating MET kinase rearrangements in melanoma and Spitz tumours. Nat Commun. 27, 7174 (2015)
PubMed link      E-mail link

Reviews